Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20

被引:70
|
作者
McCraw, Dustin M. [1 ]
O'Donnell, Jason K. [2 ]
Taylor, Kenneth A. [3 ]
Stagg, Scott M. [2 ,4 ]
Chapman, Michael S. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA
[2] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA
[3] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA
[4] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA
基金
美国国家卫生研究院;
关键词
Adeno-associated virus; Antibody; A20; Epitope; Fab'; Gene therapy; Monoclonal; AAV2 CAPSID GENE; ELECTRON-MICROSCOPY; IMMUNE-RESPONSES; RECEPTOR-BINDING; VIRAL VECTORS; FACTOR-IX; TRANSDUCTION; THERAPY; PARVOVIRUS; IDENTIFICATION;
D O I
10.1016/j.virol.2012.05.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5 angstrom resolution is determined for a complex of AAV-2 with the Fab' fragment of monoclonal antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is determined through fitting the cryo-EM reconstruction with a homology model following sequencing of the variable domain, and provides a structural basis for integrating diverse prior epitope mappings. The footprint extends from the previously implicated plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated. Comparison with structures of binding and non-binding serotypes indicates that recognition depends on a combination of subtle serotype-specific features. Separation of the neutralizing epitope from the heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can still bind to target cells. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 50 条
  • [1] Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes
    West, Cara
    Federspiel, Joel D.
    Rogers, Kara
    Khatri, Arpana
    Rao-Dayton, Sheila
    Ocana, Mireia Fernandez
    Lim, Sean
    D'Antona, Aaron Michael
    Casinghino, Sandra
    Somanathan, Suryanarayan
    HUMAN GENE THERAPY, 2023, 34 (11-12) : 554 - 566
  • [2] Prediction of adeno-associated virus neutralizing antibody activity for clinical application
    Wang, M.
    Crosby, A.
    Hastie, E.
    Samulski, J. J.
    McPhee, S.
    Joshua, G.
    Samulski, R. J.
    Li, C.
    GENE THERAPY, 2015, 22 (12) : 984 - 992
  • [3] Adeno-associated virus-2 and its primary cellular receptor-Cryo-EM structure of a heparin complex
    O'Donnell, Jason
    Taylor, Kenneth A.
    Chapman, Michael S.
    VIROLOGY, 2009, 385 (02) : 434 - 443
  • [4] Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion
    Chai, Zheng
    Sun, Junjiang
    Rigsbee, Kelly Michelle
    Wang, Mei
    Samulski, R. Jude
    Li, Chengwen
    JOURNAL OF CONTROLLED RELEASE, 2017, 262 : 348 - 356
  • [5] Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies
    Lotfinia, Majid
    Abdollahpour-Alitappeh, Meghdad
    Hatami, Behzad
    Zali, Mohammad Reza
    Karimipoor, Morteza
    CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (03) : 289 - 298
  • [6] Structure of neurotropic adeno-associated virus AAVrh.8
    Halder, Sujata
    Van Vliet, Kim
    Smith, J. Kennon
    Thao Thi Phuong Duong
    McKenna, Robert
    Wilson, James M.
    Agbandje-McKenna, Mavis
    JOURNAL OF STRUCTURAL BIOLOGY, 2015, 192 (01) : 21 - 36
  • [7] Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies
    Sun, Junjiang
    Hua, Baolai
    Chen, Xiaojing
    Samulski, Richard J.
    Li, Chengwen
    HUMAN GENE THERAPY, 2017, 28 (08) : 654 - 666
  • [8] The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs
    Kashiwakura, Yuji
    Baatartsogt, Nemekhbayar
    Yamazaki, Shoji
    Nagao, Azusa
    Amano, Kagehiro
    Suzuki, Nobuaki
    Matsushita, Tadashi
    Sawada, Akihiro
    Higasa, Satoshi
    Yamasaki, Naoya
    Fujii, Teruhisa
    Ogura, Taemi
    Takedani, Hideyuki
    Taki, Masashi
    Matsumoto, Takeshi
    Yamanouchi, Jun
    Sakai, Michio
    Nishikawa, Masako
    Yatomi, Yutaka
    Yada, Koji
    Nogami, Keiji
    Watano, Ryota
    Hiramoto, Takafumi
    Hayakawa, Morisada
    Kamoshita, Nobuhiko
    Kume, Akihiro
    Mizukami, Hiroaki
    Ishikawa, Shizukiyo
    Sakata, Yoichi
    Ohmori, Tsukasa
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2022, 27 : 404 - 414
  • [9] Characterization of the Serpentine Adeno-Associated Virus (SAAV) Capsid Structure: Receptor Interactions and Antigenicity
    Mietzsch, Mario
    Hull, Joshua A.
    Makal, Victoria E.
    Ybargollin, Alberto Jimenez
    Yu, Jennifer C.
    McKissock, Kedrick
    Bennett, Antonette
    Penzes, Judit
    Lins-Austin, Bridget
    Yu, Qian
    Chipman, Paul
    Bhattacharya, Nilakshee
    Sousa, Duncan
    Strugatsky, David
    Tijssen, Peter
    McKenna, Robert
    Agbandje-McKenna, Mavis
    JOURNAL OF VIROLOGY, 2022, 96 (11)
  • [10] Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay
    Krotova, Karina
    Aslanidi, George
    HUMAN GENE THERAPY, 2020, 31 (19-20) : 1124 - 1131